Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Fenofibrate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA known ✓ | Q07869 | 7/20 | 0.97 |
| ▸ | CNR1 | P21554 | 7/20 | 0.97 |
| ▸ | PPARG | P37231 | 3/20 | 0.97 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.97 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.97 |
| ▸ | MEN1 | O00255 | 3/20 | 0.97 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.97 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.97 |
| ▸ | TSHR | P16473 | 2/20 | 0.97 |
| ▸ | HTR2A | P28223 | 2/20 | 0.97 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.97 |
| ▸ | MAPT | P10636 | 2/20 | 0.97 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.97 |
| ▸ | HPGD | P15428 | 2/20 | 0.97 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.97 |
| ▸ | USP2 | O75604 | 1/20 | 0.97 |
| ▸ | LMNA | P02545 | 1/20 | 0.97 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.97 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.97 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.97 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fenofibrate SCHEMBL3876232 | 0.99 | PPARA (1.00) | PPARACNR1PPARGCYP1A2CYP3A4 | |
| Fenofibrate SCHEMBL4670 | 0.99 | PPARA (1.00) | PPARACNR1PPARGCYP1A2CYP3A4 | |
| Fenofibrate SCHEMBL29262793 | 0.97 | PPARA (0.97) | PPARACNR1PPARGCYP1A2CYP3A4 | |
| Fenofibrate SCHEMBL22209064 | 0.97 | PPARA (0.97) | PPARACNR1PPARGCYP1A2CYP3A4 | |
| Fenofibrate SCHEMBL29262792 | 0.97 | PPARA (0.97) | PPARACNR1PPARGCYP1A2CYP3A4 | |
| Fenofibrate SCHEMBL27847067 | 0.97 | PPARA (0.97) | PPARACNR1PPARGCYP1A2CYP3A4 | |
| SCHEMBL31084128 | 0.95 | PPARA (0.92) | PPARACNR1PPARGCYP1A2CYP3A4 | |
| SCHEMBL31084127 | 0.95 | PPARA (0.92) | PPARACNR1PPARGCYP1A2CYP3A4 | |
| SCHEMBL21992457 | 0.91 | CNR1 (0.86) | PPARACNR1PPARGCYP1A2CYP3A4 | |
| Fenofibrate SCHEMBL4251589 | 0.91 | PPARA (0.85) | PPARACNR1PPARGCYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101823956-B | Diisopropylamine fenofibrate, preparation method thereof, pharmaceutical composition and application thereof | CAO GUIYING | 2014-09-10 | — | — | CN | claimed |
| CN-103288646-B | Preparation method of fenofibrate nitrate | SICHUAN BAILI PHARMACEUTICAL CO LTD | 2014-07-23 | — | — | CN | claimed |
| CN-102516166-A | Nicotinic acid derivative of fenofibrate and preparation method of nicotinic acid derivative | BEIJING FUKANGREN BIOPHARMACEUTICAL TECHNOLOGY CO LTD | 2012-06-27 | — | — | CN | claimed |
| CN-111138427-B | Fenofibrate acid salt of berberine and analogues thereof, crystal form, preparation method and application | 江西富祥药业股份有限公司 | 2021-09-17 | — | — | CN | disclosed |
| CN-111138427-A | Fenofibrate acid salt of berberine and analogues thereof, crystal form, preparation method and application | 江西富祥药业股份有限公司 | 2020-05-12 | — | — | CN | disclosed |
| US-10577379-B1 | Fenofibric acid salt with berberine or its analogues, crystalline forms, methods of preparation, and applications thereof | JIANGXI FUSHINE PHARMACEUTICAL CO., LTD. (CN) | 2020-03-03 | — | — | US | disclosed |
| CN-102552143-B | Pharmaceutical composition of the fenofibrate liposome containing pravastatin sodium and preparation method thereof | 海口南陆医药科技股份有限公司 | 2017-09-15 | — | — | CN | disclosed |
| CN-101823956-B | Diisopropylamine fenofibrate, preparation method thereof, pharmaceutical composition and application thereof | CAO GUIYING | 2014-09-10 | — | — | CN | disclosed |
| CN-103288646-B | Preparation method of fenofibrate nitrate | SICHUAN BAILI PHARMACEUTICAL CO LTD | 2014-07-23 | — | — | CN | disclosed |
| CN-103288646-B | Preparation method of fenofibrate nitrate | SICHUAN BAILI PHARMACEUTICAL CO LTD | 2014-07-23 | — | — | CN | disclosed |
| CN-103288646-A | Preparation method of fenofibrate nitrate | SICHUAN BIOKIN PHARMACEUTICAL CO LTD | 2013-09-11 | — | — | CN | disclosed |
| CN-102516166-A | Nicotinic acid derivative of fenofibrate and preparation method of nicotinic acid derivative | BEIJING FUKANGREN BIOPHARMACEUTICAL TECHNOLOGY CO LTD | 2012-06-27 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10577379-B1 | Fenofibric acid salt with berberine or its analogues, crystalline forms, methods of preparation, and applications thereof | CEL, LIPA, SLC10A1 | PPARA 16/4885CNR1 599/4885PPARG 108/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.